You have read all your free articles, to continue reading subscribe to read the rest of this content.
Recipharm and LIDDS have signed an exclusive collaboration agreement regarding scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS patented targeted treatment for prostate cancer. The agreement will be an important component for the upcoming Phase IIb study which isAlready a subscriber Login You have read all…
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe Ilya is at the forefront of science by developing what can be the next advancement in biologics, tissue regeneAlready a…
The company has secured a private placement, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications. The company’s lead investigational candidate drug is currently beAlready a subscriber Login You have…
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the European Union as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specificallAlready a subscriber Login You have read all your free articles,…
